| Bioequivalence of Two Different Capsule Types of Dabigatran (NCT01290757) | Boehringer Ingelheim | 2011-01-01 |
| Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma (NCT01277523) | Boehringer Ingelheim | 2011-01-01 |
| Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg) (NCT01286558) | Boehringer Ingelheim | 2011-01-01 |
| Telmisartan and Amlodipine Versus Monocomponent Tablets (NCT01278797) | Boehringer Ingelheim | 2011-01-01 |
| Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food (NCT01286571) | Boehringer Ingelheim | 2011-01-01 |
| Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components (NCT01276327) | Boehringer Ingelheim | 2011-01-01 |
| Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers (NCT01284621) | Boehringer Ingelheim | 2011-01-01 |
| Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers. (NCT01276990) | Boehringer Ingelheim | 2011-01-01 |
| DDI Between BI Empagliflozin (10773) and Verapamil (NCT01276301) | Boehringer Ingelheim | 2011-01-01 |
| A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy (NCT01243268) | Boehringer Ingelheim | 2010-12-21 |
| Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma (NCT01257230) | Boehringer Ingelheim | 2010-12-01 |
| Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers (NCT01214109) | Boehringer Ingelheim | 2010-12-01 |
| CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes (NCT01243424) | Boehringer Ingelheim | 2010-11-11 |
| A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects (NCT01248364) | Boehringer Ingelheim | 2010-11-01 |
| Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis (NCT01241539) | Boehringer Ingelheim | 2010-11-01 |
| A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel (NCT01251653) | Boehringer Ingelheim | 2010-11-01 |
| Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers (NCT01242176) | Boehringer Ingelheim | 2010-11-01 |
| Telmisartan+Amlodipine Fixed Dose Combination in Hypertension (NCT01204398) | Boehringer Ingelheim | 2010-11-01 |
| Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma. (NCT01233284) | Boehringer Ingelheim | 2010-11-01 |
| An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours (NCT01206816) | Boehringer Ingelheim | 2010-10-04 |
| Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers (NCT02268604) | Boehringer Ingelheim | 2010-10-01 |
| BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours (NCT01214616) | Boehringer Ingelheim | 2010-10-01 |
| Tiotropium Respimat Pharmacokinetic Study in COPD (NCT01222533) | Boehringer Ingelheim | 2010-10-01 |
| Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability (NCT01211197) | Boehringer Ingelheim | 2010-10-01 |
| Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers. (NCT01215773) | Boehringer Ingelheim | 2010-10-01 |
| Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy (NCT01215097) | Boehringer Ingelheim | 2010-10-01 |
| Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control (NCT01214239) | Boehringer Ingelheim | 2010-10-01 |
| Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers (NCT01216384) | Boehringer Ingelheim | 2010-10-01 |
| Telmisartan 80mg Non-responder Trial (NCT01222520) | Boehringer Ingelheim | 2010-10-01 |
| Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers (NCT01216397) | Boehringer Ingelheim | 2010-09-01 |
| Tiotropium Bromide in Cystic Fibrosis (NCT01179347) | Boehringer Ingelheim | 2010-09-01 |
| Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus (NCT01193218) | Boehringer Ingelheim | 2010-09-01 |
| A Phase I Trial to Investigate the Metabolism and Pharmacokinetics as Well as Safety and Tolerability of a Single Dose BI671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers (NCT01205373) | Boehringer Ingelheim | 2010-09-01 |
| Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study (NCT01194830) | Boehringer Ingelheim | 2010-09-01 |
| Comprehensive Add on Study in Japan (NCT01204294) | Boehringer Ingelheim | 2010-09-01 |
| Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects (NCT01195688) | Boehringer Ingelheim | 2010-09-01 |
| Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin (NCT01210001) | Boehringer Ingelheim | 2010-09-01 |
| Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee (NCT01207973) | Boehringer Ingelheim | 2010-09-01 |
| Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome (NCT01174459) | Boehringer Ingelheim | 2010-08-01 |
| Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery (NCT01153698) | Boehringer Ingelheim | 2010-08-01 |
| Telmisartan, Amlodipine and Combination in Healthy Subjects (NCT01181011) | Boehringer Ingelheim | 2010-08-01 |
| Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I (NCT01172808) | Boehringer Ingelheim | 2010-08-01 |
| Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate (NCT01184989) | Boehringer Ingelheim | 2010-08-01 |
| Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients (NCT01191944) | Boehringer Ingelheim | 2010-08-01 |
| Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA (NCT01139658) | Boehringer Ingelheim | 2010-08-01 |
| Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food (NCT01189201) | Boehringer Ingelheim | 2010-08-01 |
| Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II (NCT01172821) | Boehringer Ingelheim | 2010-08-01 |
| Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes (NCT01167881) | Boehringer Ingelheim | 2010-08-01 |
| Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects (NCT01195675) | Boehringer Ingelheim | 2010-08-01 |
| 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks (NCT01183013) | Boehringer Ingelheim | 2010-08-01 |
| Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823 (NCT01189175) | Boehringer Ingelheim | 2010-08-01 |
| Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Volunteers. (NCT01170637) | Boehringer Ingelheim | 2010-07-01 |
| Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes (NCT01159600) | Boehringer Ingelheim | 2010-07-01 |
| Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function (NCT01111318) | Boehringer Ingelheim | 2010-07-01 |
| A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma (NCT01152450) | Boehringer Ingelheim | 2010-07-01 |
| BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours (NCT01169675) | Boehringer Ingelheim | 2010-07-01 |
| An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy (NCT01103960) | Boehringer Ingelheim | 2010-07-01 |
| BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME). (NCT01131676) | Boehringer Ingelheim | 2010-07-01 |
| Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes (NCT01177813) | Boehringer Ingelheim | 2010-07-01 |
| Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment (NCT01164501) | Boehringer Ingelheim | 2010-07-01 |
| Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF) (NCT01170065) | Boehringer Ingelheim | 2010-06-25 |
| LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment (NCT01125566) | Boehringer Ingelheim | 2010-06-22 |
| A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer (NCT01152437) | Boehringer Ingelheim | 2010-06-01 |
| Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers (NCT01146886) | Boehringer Ingelheim | 2010-06-01 |
| to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers (NCT01134965) | Boehringer Ingelheim | 2010-06-01 |
| BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours (NCT01145885) | Boehringer Ingelheim | 2010-06-01 |
| Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection (NCT01132313) | Boehringer Ingelheim | 2010-05-01 |
| Relative Bioavailability of Olodaterol and Fluconazole (NCT01153724) | Boehringer Ingelheim | 2010-05-01 |
| Relative Bioavailability of of Olodaterol and Ketoconazole (NCT01153711) | Boehringer Ingelheim | 2010-05-01 |
| Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers (NCT01111331) | Boehringer Ingelheim | 2010-05-01 |
| TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch (NCT01134393) | Boehringer Ingelheim | 2010-05-01 |
| Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data (NCT01134939) | Boehringer Ingelheim | 2010-05-01 |
| Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease (NCT01126437) | Boehringer Ingelheim | 2010-05-01 |
| Drug Use Survey of RESPIMAT in Patients With COPD (NCT01145053) | Boehringer Ingelheim | 2010-05-01 |
| Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma (NCT01122680) | Boehringer Ingelheim | 2010-05-01 |
| Safety and PK Study of BIBF 1120 in Japanese Patients With IPF (NCT01136174) | Boehringer Ingelheim | 2010-05-01 |
| To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle). (NCT01145014) | Boehringer Ingelheim | 2010-05-01 |
| BI 671800 in Asthmatic Patients on Inhaled Corticosteroids (NCT01103349) | Boehringer Ingelheim | 2010-04-20 |
| BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) (NCT01121393) | Boehringer Ingelheim | 2010-04-19 |
| Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese Healthy Volunteers (NCT01119443) | Boehringer Ingelheim | 2010-04-01 |
| Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers (NCT02172235) | Boehringer Ingelheim | 2010-04-01 |
| BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer (NCT01121406) | Boehringer Ingelheim | 2010-04-01 |
| Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients (NCT01108809) | Boehringer Ingelheim | 2010-04-01 |
| BI 671800 ED in Steroid-naive Asthmatic Patients (NCT01092143) | Boehringer Ingelheim | 2010-03-18 |
| Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease (NCT01097421) | Boehringer Ingelheim | 2010-03-01 |
| Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer (NCT01090011) | Boehringer Ingelheim | 2010-03-01 |
| Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes (NCT01084005) | Boehringer Ingelheim | 2010-03-01 |
| Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids (NCT01090024) | Boehringer Ingelheim | 2010-03-01 |
| Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects (NCT02224105) | Boehringer Ingelheim | 2010-03-01 |
| Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment (NCT01087502) | Boehringer Ingelheim | 2010-03-01 |
| Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age (NCT01083732) | Boehringer Ingelheim | 2010-03-01 |
| Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease (NCT01072396) | Boehringer Ingelheim | 2010-02-01 |
| Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female Volunteers (NCT02221388) | Boehringer Ingelheim | 2010-02-01 |
| A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma. (NCT01013753) | Boehringer Ingelheim | 2010-02-01 |
| LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (NCT01085136) | Boehringer Ingelheim | 2010-02-01 |
| Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects (NCT02223026) | Boehringer Ingelheim | 2010-01-01 |
| Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (NCT01040689) | Boehringer Ingelheim | 2010-01-01 |
| A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (NCT01040728) | Boehringer Ingelheim | 2010-01-01 |
| Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers (NCT02220647) | Boehringer Ingelheim | 2010-01-01 |
| Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers (NCT02221414) | Boehringer Ingelheim | 2010-01-01 |